TY - JOUR
T1 - Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy
T2 - a retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association
AU - The Registration Committee of the Japanese Gastric Cancer Association
AU - Katai, Hitoshi
AU - Ishikawa, Takashi
AU - Akazawa, Kohei
AU - Fukagawa, Takeo
AU - Isobe, Yoh
AU - Miyashiro, Isao
AU - Oda, Ichiro
AU - Tsujitani, Shunichi
AU - Ono, Hiroyuki
AU - Tanabe, Satoshi
AU - Nunobe, Souya
AU - Suzuki, Satoshi
AU - Kakeji, Yoshihiro
N1 - Publisher Copyright:
© 2020, The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Background: No guidelines are available for defining the extent of lymph node (LN) dissection in patients with remnant gastric carcinoma (RGC). Hence, this retrospective study aimed to determine the optimal extent of LN dissection in patients with RGC. Methods: We retrospectively evaluated the therapeutic outcomes of node dissection for RGC from a nationwide registry. When the metastatic rate or 5-year survival rate exceeded 10%, dissection was recommended. We calculated the dissection index by multiplying the incidence of metastasis at that nodal station by the 5-year survival rate of patients with metastasis at the station. A dissection index of > 1.0 was considered significant. Results: We included 1133 patients with RGC (T2–T4 tumor) who had undergone distal gastrectomy as the primary surgery for the evaluation of the survival benefit of nodal dissection. Any regional node station was considered significant. When the primary surgery was for malignant disease, the index was high for Nos. 3 (10.2), 7 (9.5), 1 (7.1), and 9 (8.0) nodes. For nodes at the splenic hilum, the index value was 4.4, which was higher than that for the perigastric nodes (Nos. 4sa and 4sb). The index for No. 10 nodes was the highest (10.5) when tumors involved a greater curvature. Conclusions: The therapeutic strategy for RGC remains the same, regardless of the histology of the primary disease during the initial surgery. Total gastrectomy and dissection of the perigastric LNs (Nos. 1–4), suprapancreatic LNs (Nos. 7–9 and 11), and LNs at the splenic hilum (No. 10) are justified.
AB - Background: No guidelines are available for defining the extent of lymph node (LN) dissection in patients with remnant gastric carcinoma (RGC). Hence, this retrospective study aimed to determine the optimal extent of LN dissection in patients with RGC. Methods: We retrospectively evaluated the therapeutic outcomes of node dissection for RGC from a nationwide registry. When the metastatic rate or 5-year survival rate exceeded 10%, dissection was recommended. We calculated the dissection index by multiplying the incidence of metastasis at that nodal station by the 5-year survival rate of patients with metastasis at the station. A dissection index of > 1.0 was considered significant. Results: We included 1133 patients with RGC (T2–T4 tumor) who had undergone distal gastrectomy as the primary surgery for the evaluation of the survival benefit of nodal dissection. Any regional node station was considered significant. When the primary surgery was for malignant disease, the index was high for Nos. 3 (10.2), 7 (9.5), 1 (7.1), and 9 (8.0) nodes. For nodes at the splenic hilum, the index value was 4.4, which was higher than that for the perigastric nodes (Nos. 4sa and 4sb). The index for No. 10 nodes was the highest (10.5) when tumors involved a greater curvature. Conclusions: The therapeutic strategy for RGC remains the same, regardless of the histology of the primary disease during the initial surgery. Total gastrectomy and dissection of the perigastric LNs (Nos. 1–4), suprapancreatic LNs (Nos. 7–9 and 11), and LNs at the splenic hilum (No. 10) are justified.
KW - Lymph node dissection
KW - Remnant gastric carcinoma
KW - Upper GI
UR - https://www.scopus.com/pages/publications/85085007042
U2 - 10.1007/s10120-020-01081-5
DO - 10.1007/s10120-020-01081-5
M3 - 記事
C2 - 32419120
AN - SCOPUS:85085007042
SN - 1436-3291
VL - 23
SP - 1091
EP - 1101
JO - Gastric Cancer
JF - Gastric Cancer
IS - 6
ER -